Table II.
Telomere lengths of persistent and non-persistent clonotypes from the administered TIL samples and their clinical responses
| Administered TIL sample | Patient clinical responsea | Persistent clonotypeb | Telomere length (Kb) | Non-persistent clonotypec | Telomere length (Kb) |
|---|---|---|---|---|---|
| TIL 2208 | CR | N/Ad | N/A | VB17a (48%→0%)e | 6.48f, g |
| VB17b (9%→0%) | |||||
| TIL 1913 | PR | N/A | N/A | VB1 (16%→0%) | 4.27 |
| TIL 1931 | PR | F4-MART-1 (20%→83%) | 8.91 | F5-MART-1 (24%→0%) | 4.61 |
| TIL 1954 | PR | VB8 (10%→5%) | 6.59 | VB3 (13%→0%) | 4.67 |
| VB14 (5%→0%) | 4.18 | ||||
| TIL 1963 | PR | VB5.1 (23%→7%) | 7.26 | N/A | N/A |
| VB7 (65%→77%) | 8.04 | ||||
| TIL 2026 | PR | VB2 (65%→8%) | 5.21 | N/A | N/A |
| TIL 2035 | PR | VB1 (1%→9%) | 5.32 | VB2 (9%→0%) | 4.73 |
| VB17 (31%→0%) | 4.56 | ||||
| TIL 2109 | PR | N/A | N/A | VB2 (32%→0%) | 3.49 |
| VB5.1 (17%→0%) | 2.94 | ||||
| TIL 2122 | PR | VB16 (45%→20%) | 4.50 | VB13.1 (6%→0%) | 4.34 |
| TIL 2149 | PR | VB8a (19%→7%) | 6.06 g | VB17 (5%→0%) | 4.12 |
| VB8b (6%→1%) | |||||
| TIL 2154 | PR | N/A | N/A | VB2 (15%→0%) | 6.76 |
| VB4 (26%→0%) | 4.11 | ||||
| TIL 2162 | PR | VB11 (50%→7%) | 5.00 | VB17 (13%→0%) | 4.31 |
| TIL 2037 | NR | VB5.1a (27%→9%) | 6.09 g | N/A | N/A |
| VB5.1b (26%→7%) | |||||
| VB7 (2%→17%) | 4.76 | ||||
| TIL 1941 | NR | N/A | N/A | VB3 (91%→0%) | 3.84 |
| Mean ± SE | 6.16 ± 0.43 | Mean ± SE | 4.49 ± 0.25 | ||
| Mann-Whitney U test | P<0.001 | ||||
Patient clinical response: CR, complete response; PR, partial response; NR, no response.
Persistent clonotypes are defined as TRBV Sequences, determined by 5’RACE analysis, that were derived from the administered TILs and present at levels ≥5% in PBMC samples obtained from melanoma patients at one month after TIL administration.
Non-persistent clonotypes are defined as TRBV sequences, determined by 5’RACE analysis, that were represented at levels ≥5% of the administered TILs and that were present at levels ≤ 1% in PBMC samples obtained at one month after TIL administration.
N/A: Either the corresponding antibodies were not available to detect and isolate the specific TRBV sequences, or none of TRBV sequences from the administered TILs met the criteria used to define either persistent clonotypes or non-persistent clonotypes.
The first number in the parenthesis represents the percentage of specific clonotype TRBV sequences in the administered TILs, and the second represents the percentage of specific clonotype TRBV sequences in PBMC samples obtained at one month after TIL administration.
Both persistent and non-persistent clonotypes were sorted from the administered TIL samples using magnetic beads as described in the materials and methods, and expressed the appropriate marker on >95% of the sorted cells.
Average of two clonotypes.